Heparan sulfate proteoglycans (HSPGs) play a crucial role in growth regulation by assembling signaling complexes and presenting growth factors to their cognate receptors. Within the immune system, expression of the HSPG syndecan-1 (CD138) is characteristic of terminally differentiated B cells, plasma cells, and their malignant counterpart, multiple myeloma (MM). This study explored the hypothesis that syndecan-1 might promote growth factor signaling and tumor growth in MM. For this purpose, the interaction was studied between syndecan-1 and hepatocyte growth factor (HGF), a putative paracrine and autocrine regulator of MM growth. The study demonstrates that syndecan-1 is capable of binding HGF and that this growth factor is indeed a potent stimulator of MM survival and proliferation. Importantly, the interaction of HGF with heparan sulfate moieties on syndecan-1 strongly promotes HGF-mediated signaling, resulting in enhanced activation of Met, the receptor tyrosine kinase for HGF. Moreover, HGF binding to syndecan-1 promotes activation of the phosphatidylinositol 3-kinase/protein kinase B signaling pathways, signaling routes that have been implicated in the regulation of cell survival and proliferation, respectively. These results identify syndecan-1 as a functional coreceptor for HGF that promotes HGF/Met signaling in MM cells, thus suggesting a novel function for syndecan-1 in MM tumorigenesis. (Blood. 2002;99:1405-1410)
migration of B cells and is a putative regulator of tumor growth in both MM and PEL. Importantly, syndecan-1 strongly promotes HGF-induced signaling through Met, the receptor tyrosine kinase for HGF, resulting in enhanced activation of signaling pathways involved in the control of cell proliferation and survival.

**Materials and methods**

**Antibodies**

Mouse monoclonal antibodies (mAbs) used were anti–syndecan-1 (CD138, clone B-B4, immunoglobulin G1 [IgG1]; Coulter Immunotech, Marseille, France); anti–syndecan-2, 10F4 (IgG1); anti–syndecan-4, 8G3 (IgG1); anti–glypican-1, S1 (IgG1) (all kindly provided by Dr G. David, Center for Human Genetics, University of Leuven, Leuven, Belgium); anti-HGF, 24 612.111 (IgG1; R&D Systems, Abingdon, United Kingdom); anti–heparan sulfate, 10E4 (IgM; Seikagaku, Tokyo, Japan), anti–desaturated uronate from heparitinase-treated heparan sulfate (ΔHS stub), 3G10 (IgG2b; Seikagaku); and antiphosphophosphotyrosine, PY-20 (IgG2b; Affiniti, Nottingham, United Kingdom). Polyclonal antibodies were used: rabbit anti-Met, C-12 (IgG; Santa Cruz Biotechnology, Santa Cruz, CA); rabbit antiphospho protein kinase B (PKB)/Akt (Ser 473); rabbit antiphospho p44/42 mitogen-activated protein (MAP) kinase (Thr 202/Tyr 204) (both New England Biolabs, Milton, United Kingdom); R-phycocerythrin–conjugated goat antirabbit (Southern Biotechnology, Birmingham, AL); horseradish peroxidase (HRP)–conjugated rabbit antimouse; (DAKO, Glostrup, Denmark); and HRP-conjugated goat antirabbit (DAKO).

**Cell lines, primary myeloma cells, and transfectants**

MM cell line XG-1 was described elsewhere. LME-1 was isolated from a patient with MM at the Department of Hematology, Academic Medical Center, Amsterdam, The Netherlands. MM cell lines were cultured in Iscoves medium (Gibco BRL/Life Technologies, Breda, The Netherlands) containing 10% fetal calf serum (Integro, Zaandam, The Netherlands), 100 IU/mL penicillin, and 100 IU/mL streptomycin (Life Technologies), 20 μg/mL human recombinant transferrin (Sigma, Bornem, Belgium), 50 μM β-mercapto ethanol, and 500 pg/mL interleukin 6 (IL-6) (R&D Systems).

Primary myeloma (PM) cells were obtained by the pleural effusion of a patient with MM. Mononuclear cells were harvested by standard Ficoll-Paque density gradient centrifugation (Amersham Pharmacia, Uppsala, Sweden) and kept on a stromal cell feeder-layer in Iscoves medium (Gibco BRL/Life Technologies) containing 10% fetal calf serum (Integro), 100 IU/mL penicillin, and 100 IU/mL streptomycin (Life Technologies). For signaling experiments, primary tumor cells (containing more than 97% plasma cells) were serum starved for 24 hours in the presence of 2% fetal calf serum, after which the cells were kept under serum-free conditions for 3 hours. The Burkitt lymphoma cell line Namalwa was purchased from American Type Culture Collection (ATCC, Rockville, MD). The Met-transfected Namalwa (NamMET) was described previously. Syndecan-1– and glypican-1–transfected Namalwa cells (NamSYN and NamGLYP) were obtained by electroporation using the eukaryotic expression vector pCDNA3 containing the full-length human syndecan-1 complementary DNA or glypican-1 complementary DNA (kindly provided by Dr G. David). Transfectants were selected in medium containing 1.6 mg/mL neomycin (Sigma). Syndecan-1– and glypican-1–positive cells were subcloned by using a FACStar flow cytometer (Becton Dickinson, Mountain View, CA). Namalwa cells were cultured in RPMI 1640 (Life Technologies) supplemented with 10% Fetal Clone I serum (HyClone Laboratories, Logan, UT), 10% fetal calf serum (Integro), 2 mM L-glutamine, 100 IU/mL penicillin, and 100 IU/mL streptomycin (all Life Technologies).

**Enzyme treatments**

For enzymatic cleavage of HS, cells were treated with either 10 μM heparitinase (Flavobacterium heparinum, EC 4.2.2.8; ICN Biomedicals, Aurora, OH) or, as control, 50 μM chondroitinase ABC (Proteus vulgaris, EC 4.2.2.4; Boehringer Mannheim, Almere, The Netherlands). The cleavage of HS by heparitinase was determined by the loss of cell surface–expressed HS (mAb 10E4) and the simultaneous gain of HS-stub expression (mAb 3G10).

**Flow-activated cell sorter analysis**

Flow-activated cell sorter (FACS) analyses using a single staining technique were described previously. For binding of recombinant human HGF (R&D Systems) or mutant HP1, cells were incubated with saturating concentrations for 1 hour at 4°C before the antibody incubations. Washing with FACS buffer followed this step.

**Immunoprecipitation and Western blot analysis**

Immunoprecipitation and Western blotting were performed as described. For analysis of phosphorylation of PKB/Akt and the MAP kinases extracellular signal-related kinase (Erk)1 and Erk2, after the indicated treatments, 3 × 10⁵ cells were directly lysed in sample buffer, separated by 10% sodium dodecylsulfate–polyacrylamide gel electrophoresis, and blotted. Equal loading was confirmed by Ponceau S staining of the blot. The part of the blot above 130 kd was stained with anti-Met (C12), the middle part (50 to 130 kd) was stained with antiphospho PKB/Akt, and the bottom part (below 50 kd) was stained with antiphospho MAP kinase antisera (all from New England Biolabs). Primary antibodies were detected by HRP-conjugated goat anti-rabbit or HRP-conjugated rabbit anti-mouse.

**Cell proliferation assay**

Cells were plated in 96-well flat-bottom tissue culture plates (Costar, Cambridge, MA) at a density of approximately 100 000 cells/mL (200 μL per well) in the absence of IL-6 and serum, in supplemented Iscoves medium as described above. HGF was added, and cells were cultured for 7 days. Cell numbers and viability were determined by adding propidium iodide and analysis on a FACScalibur (Becton Dickinson). For proliferation, the cultures were pulsed with 0.0185 MBq (0.5 μCi) (methyl-3H) thymidine (321.9 × 10⁶ Bq/mmol [87 Ci/mmol]; Amersham Life Science, Little Chalfont, United Kingdom) during the last 4 hours. Results are expressed as counts per minute (cpm). Error bars represent the SD values of triplicate measurements.

**Results**

**Expression of HS moieties and proteoglycan core proteins on MM cells**

Expression of the HSPG syndecan-1 as well as Met, the receptor tyrosine kinase for HGF, is common on MM cells. This expression suggests that HGF might not only interact with Met but also with syndecan-1, resulting in a ternary interaction between Met, HGF, and syndecan-1 at the MM cell surface. This ménage a trois might promote tumorigenesis. To explore this hypothesis, we used 2 MM cell lines, ie, XG-1 and LME-1, as well as primary tumor cells from a patient with MM patient (PM). FACS analysis demonstrated that these cells express high levels of both HS and syndecan-1 (Figure 1) but lack expression of other proteoglycan core proteins, including other syndecans, glypican-1, and CD44v3 (data not shown). In accordance with these FACS data, a single HSPG of approximately 90 kd was detected by immunoblotting in the cell lysates of XG-1, LME-1, and PM cells (Figure 1C, left panel). A HSPG of similar size was also present in the lysates of syndecan-1–transfected Namalwa Burkitt lymphoma cells (NamSYN), but not in that of untransfected (Nam) or glypican-1–transfected cells (Figure 1C, left panel). Stripping and
restaining the blot with an antis Syndecan-1 mAb confirmed that this 90-kd HSPG represents Syndecan-1 (Figure 1C, right panel), indicating that Syndecan-1 is the major, and presumably only, HSPG expressed by XG-1, LME-1, and PM cells studied.

Stimulation of MM cells with HGF leads to activation of the phosphatidylinositol 3-kinase/PKB and RAS/MAP kinase pathways as well as cell proliferation

In addition to expressing Syndecan-1, the XG-1, LME-1, and PM cells express Met and possess a functional Met signaling pathway (Figure 2). Stimulation of XG-1 and LME-1 with HGF resulted in a rapid tyrosine phosphorylation of Met (Figure 2A) as well as phosphorylation of PKB/Akt and the MAP kinases Erk1 and Erk2 (Figure 2B). In the PM cells we also observed a strong HGF-induced serine phosphorylation of PKB/Akt, whereas the phosphorylation of MAP kinases Erk1 and Erk2 increased approximately 2-fold (Figure 2B). Hence, signaling by Met in these MM cells leads to activation of phosphatidylinositol (PI3-K)/PKB as well as RAS/MAP kinase pathways, signaling routes that have been implicated in the regulation of cell survival and proliferation.

Figure 2. HGF/Met signaling in MM.

(A) HGF stimulation induces Met activation in XG-1 and LME-1. Cells were incubated for 2 minutes in the absence or presence of HGF. Met activation was assessed by immunoprecipitation and subsequent immuno-blotting with antiphosphotyrosine antibodies. (B) HGF stimulation induces activation of both PKB/Akt and MAP kinases. Activation of PKB/Akt and MAP kinases was determined in total cell lysates of XG-1, LME-1, and MC cells and immunoblotted with antiphospho PKB/Akt (top) and antiphospho Erk1 and Erk2 (α-p-MAPK) (middle), respectively. The Met-expressing Burkitt cell line Nam MET was used as a positive control. Stainings with antihuman Met represent loading controls (A,B bottom panels).

Figure 3. HGF-induced proliferation of MM cells.

(A) HGF mediates increased survival in XG-1. Cells were grown in the absence of IL-6 and serum, and HGF was added at a concentration of 200 ng/mL. Viability was measured by FACS analysis on days 0, 3, 5, and 7, using propidium iodide incorporation. On day 0, relative viability was set at 100%. (B) HGF is a potent growth factor for XG-1. Culture conditions were as in (A), HGF was added in the concentration shown, and the number of viable cells was quantified by using propidium iodide incorporation and FACS analysis at days 0, 3, 5, and 7. (C) HGF induces proliferation in XG-1. Cells were cultured as in (A), and HGF was added in the concentrations shown. 3H thymidine incorporation was measured on days 3 and 4. Error bars represent the SD of a triplicate measurement.
prived of IL-6, a cytokine required for their propagation in vitro, decreased affinity for HS, showed only a weak binding to the MM can-1 and heparitinase but not chondroitinase ABC; pretreatment binding was largely dependent on HS moieties decorating syndecan. Namalwa cells bound virtually no HGF. Importantly, this HGF found to bind high levels of HGF (Figure 4), whereas wild-type cells bound little or none. To determine the involvement of HS in HGF binding, cells were treated with either heparitinase or chondroitinase ABC before incubation with HGF. Binding of HGF or HP1 is shown as the mean fluorescence intensity (MFI) of cells incubated with HGF or HP1, washed, and stained with a HGF-specific mAb, minus the MFI of identical cells not incubated with HGF.

Discussion

Recently, biochemical, cell biologic, and genetic studies have converged to reveal that integral membrane HSPGs are critical regulators of growth and differentiation of epithelial and connective tissues. By immobilizing and oligomerizing cytokines and by presenting them to their high affinity receptors, HSPGs create niches in the microenvironment and regulate cytokine responses. Because a vast number of cytokines and growth factors involved in the growth and differentiation of normal and neoplastic lymphocytes contain potential HS binding sites, HSPGs presumably also play important roles in the immune response and in the development and progression of lymphoid tumors. However, the expression and function of HSPGs on the cell surface of normal and neoplastic lymphocytes has thus far remained largely unexplored. In the present study, we investigated the expression and function of HSPGs on MM cell lines and primary MM tumor cells. We demonstrate that the HSPG syndecan-1 on MM cells is capable of binding HGF. This interaction promotes signaling through Met, the receptor tyrosine kinase for HGF, and regulates the activity of signaling pathways that control cell proliferation and survival.

Our findings present the first direct evidence that syndecan-1 regulates growth factor signaling in MM. Cell surface–expressed syndecan-1 presumably acts by increasing the effective concentration of HGF on the plasma membrane, an effect that may be modulated by soluble syndecan-1 shed from the MM cell surface, whereas the binding of several HGF molecules to syndecan-1 may promote dimerization and oligomerization of Met, leading to enhanced receptor activation (Figure 6). Alternatively, by inducing a conformational change, syndecan-1 might influence the affinity of HGF for Met, as has been demonstrated for HSPG binding of the NK1 splice variant of HGF.

Furthermore, the polarized distribution of syndecan-1, as observed on myeloma cells, may impose a constraint on the spatial

**Figure 4.** Syndecan-1 binds HGF by its heparan sulfate side chains. MM cell lines XG-1 and LME-1 and PM cells, Nam and NamSYN, were analyzed by FACS for their capacity to bind HGF or the HGF mutant HP1. To determine the involvement of HS in HGF binding, cells were treated with either heparitinase or chondroitinase ABC before incubation with HGF. Binding of HGF or HP1 is shown as the mean fluorescence intensity (MFI) of cells incubated with HGF or HP1, washed, and stained with a HGF-specific mAb, minus the MFI of identical cells not incubated with HGF.

**Figure 5.** Syndecan-1 promotes HGF-induced activation of Met, PKB/Akt, and MAP kinase. To assess the contribution of syndecan-1 to HGF-induced signaling, MM cell line XG-1 and PM cells were treated with heparitinase (HT) before stimulation with HGF. (A) Activation of Met. Met activation in XG-1 was assessed by immunoprecipitation and subsequent immunoblotting with antiphosphotyrosine antibodies. (B) Activation of PKB/Akt and MAP kinase. Activation of PKB/Akt and the MAP kinases Erk1 and Erk2 was determined in total cell lysates of XG-1 immunoblotted with antiphospho PKB/Akt (top) and antiphospho Erk1 and Erk2 (α p-MAPK) (middle), respectively. (C) Activation of PKB/Akt and MAP kinase. Activation of PKB/Akt and the MAP kinases Erk1 and Erk2 was determined in total cell lysates of PM cells, immunoblotted with antiphospho PKB/Akt (top) and antiphospho Erk1 and Erk2 (α p-MAPK) (middle), respectively. Staining with anti-Met was used to verify equal loading (A,B,C bottom panels). Activation of PKB/Akt and MAP kinase by insulin, which does not bind to HS, was unaffected (Figure 5B and C).
growth, and protection from apoptosis. The HGF/Met pathway has also been implicated in B-cell development and neoplasia. During normal B-cell differentiation, Met is expressed at the GC and plasma cell stage, whereas HGF is produced by follicular dendritic cells and by bone marrow stromal cells. HGF stimulation of B lymphocytes leads to enhanced integrin activity, promoting cell adhesion to VCAM-1, a major integrin ligand on follicular dendritic cells as well as B-cell migration. Interestingly, in GC cells, presentation of HGF by the HSPG CD44v3 promotes Met signaling. In B-cell malignancies, the HGF/Met pathway may promote tumorigenesis through both autocrine and paracrine mechanisms. In PEL, as well as MM, Met and HGF are often coexpressed, suggesting autocrine stimulation. Because bone marrow stromal cells have been reported to produce HGF, paracrine stimulation of MM cells may also take place within the bone marrow microenvironment. Consistent with a role for the HGF/Met in MM progression, high serum levels of HGF were reported to be associated with unfavorable prognosis in patients with MM.

The biologic processes controlled by the HGF/Met pathway in MM cells are as yet incompletely defined. Our current study demonstrates that HGF can promote tumor growth (Figure 3), a function presumably involving transcription regulatory signals delivered through the activated RAS/PI3-K kinase pathway (Figure 2B). In addition, HGF stimulation might also affect tumor dissemination and/or tumor cell survival. A role in MM dissemination is suggested by the fact that HGF has been shown to regulate integrin activity on GC B cells and promotes adhesion and migration of Burkitt lymphoma cell lines. Key regulatory molecules implicated in inside-out signaling to integrins are PI3-K and different RAS-like guanosine triphosphatases, the activity of which can be controlled by HGF/Met. In MM cell survival, the HGF/Met pathway may also play a critical part. Studies in several cell types, including liver cell precursors and carcinoma cells, have indicated that the HGF/Met pathway can generate potent survival signals. Antiapoptotic signals in MM might be transduced through the PI3-K/PI3-K pathway, which was activated by HGF in our MM cell lines and primary tumor cells (Figure 2B). PKB/Akt is able to phosphorylate BAX, a BCL-2 antagonist expressed in B cells, and may thereby suppress the proapoptotic effects of BAD.

In conclusion, our present findings demonstrate that syndecan-1 strongly promotes HGF/Met signaling, resulting in enhanced activation of signaling pathways involved in the control of cell proliferation and survival. Clearly, this regulatory role of syndecan-1 may not be limited to the HGF/Met pathway but may extend to its high affinity receptor. Further studies are necessary to determine the precise mechanisms through which syndecan-1 promotes HGF/Met signaling in MM cells.

Acknowledgments

We thank S. de Jong, J. Dobber, E. A. Beuling, and T. A. M. Wormhoudt for excellent technical assistance.

References

Cell surface proteoglycan syndecan-1 mediates hepatocyte growth factor binding and promotes Met signaling in multiple myeloma

Patrick W. B. Derksen, Robert M. J. Keehnen, Ludo M. Evers, Marinus H. J. van Oers, Marcel Spaargaren and Steven T. Pals